Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

An update from Roivant Sciences ( ($ROIV) ) is now available. On September 16, 2026, Roivant Sciences Ltd. held its 2026 Annual General Meeting of ...

Roivant Shareholders Approve Directors and Governance Matters

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spruce Biosciences (SPRB) and Roivant Sciences (ROIV...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, from Leerink Partners maintained a Buy rating on Roivant Sciences, with a price target of $52.00. The word on The Stree...

Leerink Partners Sticks to Their Buy Rating for Roivant Sciences (ROIV)

An announcement from Roivant Sciences ( ($ROIV) ) is now available. On September 8, 2026, Roivant reported positive Phase 2 PHocus trial data for m...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ROIV	$36.13	-1.87%	5.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ROIV	$36.13	-1.9%	5.66M
3
4
5
6

ROIV

Get Roivant Sciences Ltd. Data in Excel

Get Roivant Sciences Ltd. Data in Excel